Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta‐analysis
Neuropsychopharmacology Reports · 2024-03 · 44 (1) · 165-175
DOI: 10.1002/npr2.12414 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 14.01.2024. Verfasst von Taro Kishi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan. Hauptthemen laut MEDLINE: Major Depressive Disorder, Thiophenes, Quinolones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aim
This systematic review and frequentist network meta‐analysis used random‐effects models is conducted to determine whether there are differences in the efficacy, acceptability, tolerability, and safety profiles of brexpiprazole (BRE) and aripiprazole (ARI) for Japanese with major depressive disorder (MDD) who were inadequately responsive to antidepressants.
Methods
Outcome measures were scores on the Montgomery Åsberg Depression Rating Scale (primary), the Clinical Global Impression severity scale, and social functioning scale; the non‐response rate; the non‐remission rate; all‐cause discontinuation; discontinuation due to adverse events (DAE); at least one adverse event (1AE); serious adverse event, akathisia; tremor; weight gain.
Results
A literature search identified three double‐blind, randomized, placebo‐controlled trials. These comprised one BRE study (with a 1 mg/day [BRE1] and a 2 mg/day [BRE2]) and two ARI studies (with a 3 mg/day arm and a flexible‐dose arm[within the dosage range approved in Japan]) ( n = 1736). Both BRE and ARI demonstrated better efficacy than the placebo. BRE but not ARI had a higher DAE than the placebo. ARI but not BRE had a higher 1AE than the placebo. BRE and ARI had a higher risk of akathisia and weight gain than the placebo. There were no significant differences between BRE and ARI for any of the outcomes. Although BRE1 had good efficacy, it carried risk of weight gain. Although BRE2 also had efficacy, it carried risks of DAE, akathisia, and weight gain. However, the risk of akathisia in BRE2 was reduced by an initial dose of 0.5 mg/day rather than 1.0 mg/day.
Conclusions
Overall BRE showed similar utility to ARI and a good risk–benefit balance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.
- Department of Neuropsychiatry, School of Medicine, St. Marianna University, Kawasaki, Japan.
- Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
ORCID-Profile: Taro Kishi, Masaki Kato
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kishi, T., Sakuma, K., Saito, T., Nakagawa, A., Kato, M., & Iwata, N. (2024). Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta‐analysis. Neuropsychopharmacology Reports, 44(1), 165-175. https://doi.org/10.1002/npr2.12414
Vancouver
Kishi T, Sakuma K, Saito T, Nakagawa A, Kato M, Iwata N. Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta‐analysis. Neuropsychopharmacology Reports. 2024;44(1):165-175. doi:10.1002/npr2.12414
BibTeX
@article{Kishi2024,
author = {Kishi, Taro and Sakuma, Kenji and Saito, Takeo and Nakagawa, Atsuo and Kato, Masaki and Iwata, Nakao},
title = {Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta‐analysis},
journal = {Neuropsychopharmacology Reports},
year = {2024},
volume = {44},
number = {1},
pages = {165--175},
doi = {10.1002/npr2.12414}
}
EUVIMED